Treatment of glomus jugulare tumors with gamma knife radiosurgery

Abstract

GKS is an effective treatment option for patients with GJTs, including those with prior surgical resection. Marginal radiation doses greater than 13 Gy may be optimal for tumor control. Longer follow-up will better define the benefits and risks of stereotactic radiosurgery in treating patients with GJT.

Workforce Analysis of Neurotologists in the United States

“…There has been a substantial shift in management of vestibular schwannomas with a greater emphasis on radiation treatment or nonsurgical management (11,13Y15). Management of other cranial base tumors, such as glomus jugulare, are also increasingly treated with focused radiotherapy with the intent of minimizing progression rather than surgery with intent of tumor eradication (16,17). These shifts in management paradigms intend to minimize new cranial nerve deficits and improve outcomes.…”

Treatment Outcomes for Single Modality Management of Glomus Jugulare Tumors With Stereotactic Radiosurgery

“…On average, the decrease in size of tumors treated in our study was 37% is comparable to other centers that have studied tumor response to GKRS. 9,12,17,21–25 These are slow growing tumors and it is important to follow these tumors over longer periods of time to assess for control of growth.…”

Endovascular Approach to Glomus Jugulare Tumors

“…Glomus tumors, also known as paragangliomas or chemodectomas, are benign neuroendocrine tumors derived from the glomus cells of the vegetative nervous system [1,2]. They can be found in a wide range of locations in the human body [3].…”

“…These types of paragangliomas are termed glomus jugular or jugulotympanic tumors (GJTs) and are the most common tumors that develop in the jugular foramen [4]. Glomus tumors are rare, with an incidence of about 1 per 1 million and a marked predisposition in women [1,3,5]. The majority of these tumors are slow-growing with a clinical manifestation in the sixth to seventh decade of life [1,3].…”

“…Glomus tumors are rare, with an incidence of about 1 per 1 million and a marked predisposition in women [1,3,5]. The majority of these tumors are slow-growing with a clinical manifestation in the sixth to seventh decade of life [1,3]. The typical expansive and locally destructive growth pattern of glomus jugulare tumors leads to cranial nerve damage with related symptoms (facial palsy, pulsatile tinnitus, hearing loss, difficulty in swallowing and loss of voice) and in larger tumors brainstem compression can be seen [1–3,5].…”